Compare NWE & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWE | ABCL |
|---|---|---|
| Founded | 1923 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2023 | 2020 |
| Metric | NWE | ABCL |
|---|---|---|
| Price | $71.78 | $11.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $66.50 | $8.40 |
| AVG Volume (30 Days) | 317.7K | ★ 8.9M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $1,610,559,000.00 | $75,128,000.00 |
| Revenue This Year | $8.84 | N/A |
| Revenue Next Year | $5.31 | $21.85 |
| P/E Ratio | $49.50 | ★ N/A |
| Revenue Growth | 6.38 | ★ 160.56 |
| 52 Week Low | $55.50 | $2.75 |
| 52 Week High | $75.18 | $12.58 |
| Indicator | NWE | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 61.25 |
| Support Level | $68.94 | $10.44 |
| Resistance Level | $71.97 | $12.58 |
| Average True Range (ATR) | 1.26 | 0.67 |
| MACD | 0.13 | -0.19 |
| Stochastic Oscillator | 83.29 | 46.50 |
NorthWestern Energy Group Inc provides electricity and natural gas services in the Upper Midwest and Northwest of the U.S. in the states of Montana, South Dakota, Nebraska, and Yellowstone National Park. The company's primary segments include Electric, which includes the generation, purchase, transmission, and distribution of electricity, and Natural Gas, which includes the production, purchase, transmission, storage, and distribution of natural gas. It uses thermal, wind, hydro, or renewable energy in varying quantities, depending on the location of the facilities, to generate power. The company derives the majority of its revenue from the Electric segment.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.